ROLE OF MONTELUKAST AS MONOTHERAPY IN IMPROVING QUALITY OF LIFE OF AN ASTHMATIC PATIENT
Main Article Content
Keywords
Montelukast, Monotherapy, Quality of life
Abstract
Background: Inadequately treated and uncontrolled asthma significantly lowers Quality of Life and increases the risk of death.
Objective: the aim of this study was to explore the role of montelukast as monotherapy in improving quality of life of an asthmatic patient.
Methodology: The current study was conducted at the department of Pulmonology Hayatabad Medical Complex Peshawar from January 2024 to May 2024 after taking approval from the ethical committee of the institute. The 32 items of the QLQ-S evaluate four domains. Symptoms, activity, emotions, and environment control. Higher scores correspond to higher life quality. SPSS version 23.0 was used to process and analyze the data.
Results: A total of 138 individuals completed this research out of which 68 (49.27%) were female and 70 (50.72%) were male participants, with a mean age of 22 ± 8 years. The most prevalent symptoms detected were severe cough 106(76.81%), wheezing 100(72.4%), shortness of breath 98(71.0%) and Tightness of chest 89 (64.4%) respectively. In comparison to day 0, participants' scores according to the Asthma Quality of Life Questionnaire-Standard were higher on day 28 overall and in every sub-domain.
Conclusion: It was concluded from the current study that Montelukast effectively controls asthma and enhances the quality of life.
References
2. Ishmael FT. The inflammatory response in the pathogenesis of asthma. J AM Osteopath Assoc. 2011;111(11_ Suppl_7):S11-S17
3. The Global Asthma Report 2018. (2018). http://www.globalasthmareport.org/
4. To T, Stanojevic S, Moores G, et al.: Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012, 12:5.
5. Miligkos M, Bannuru RR, Alkofide H, Kher SR, Schmid CH, Balk EM: Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents:a systematic review and meta-analysis Ann Intern Med. 2015, 163:756-767
6. Global Initiative for Asthma (GINA) . (2018). https://ginasthma.org/2018-gina-report-global-strategy-forasthma-management-and-prevention
7. Baig S, Khan RA, Khan K, Rizvi N: Effectiveness and quality of life with montelukast in asthma - a doubleblind randomized control trial. Pak J Med Sci. 2019, 35:731-736.
8. Biernacki WA, Kharitonov SA, Biernacka HM, Barnes PJ: Effect of montelukast on exhaled leukotriene and quality of life in asthmatic patients. Chest. 2005, 128:1958-63
9. Virchow JC, Mehta A, Ljungblad L, Mitfessel H. MONICA Study Group: Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast In Chronic Asthma (MONICA) study. Respir Med. 2010, 104:644-51
10. Virchow JC, Bachert C: Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med. 2006, 100:1952-1959.
11. Lazarinis N, Bood J, Wheelock C, Dahlen SE, Dahlen B: The CysLT1receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma. Eur Respir J. 2015, 46:2545
12. Bozek A, Warkocka-Szoltysek B, Filipowska-Gronska A, Jarzab J: Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. J Asthma. 2012, 49:530-534.
13. Columbo M: Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast .Asthma Res Pract. 2017, 3:3
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Muhammad Fahad
Medical Officer, Internal medicine department Cat D Hospital Latambar Karak KPK Pakistan